PALATIN TECHNOLOGIES Forum: Community User: CologneFC

es kamen doch keine schlechten News oder?

aber vor was?

die Leute bekommen Angst

Hey was ist los? Warum geht es bergab?

die Leute bekommen Angst

Ganz toller Zeitpunkt für das announcement.

Es geht los und fest halten!

About Palatin Technologies, Inc.  
Palatin Technologies, Inc. is a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical need and commercial potential. Palatin's strategy is to develop products and then form marketing collaborations with industry leaders in order to maximize their commercial potential. For additional information regarding Palatin, please visit Palatin's website at www.Palatin.com. 

About Ulcerative Colitis  
Ulcerative colitis is a chronic disease of the large intestine (colon), with inflammation and ulcerations that can cause significant abdominal pain, persistent diarrhea, loss of appetite and other symptoms.  Over 700,000 individuals in the United States are affected by ulcerative colitis, with over 350,000 diagnosed with moderate-to-severe disease.  Existing treatments are not effective in a large portion of patients with moderate-to-severe ulcerative colitis, with some severe cases resulting in surgical removal of the colon.

About PL-8177  
PL-8177 is a synthetic cyclic heptapeptide with demonstrated efficacy in animal inflammatory bowel disease models.  Palatin has developed an oral formulation of PL-8177 that has been validated in animal studies, which is scheduled to be explored in future clinical investigations.  PL-8177 is a potent agonist at human MC1r, with sub-nanomolar affinity binding and EC50 functional values. 

CRANBURY, N.J., Feb. 5, 2018 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical need and commercial potential, today announced that the first healthy subjects have been dosed in a Phase 1 clinical study of PL-8177. The Phase 1 study is a randomized, double-blind, placebo-controlled, single and multiple ascending dose study intended to evaluate the safety and tolerability of PL-8177 administered via subcutaneous injection.  The study is designed to enroll up to 52 healthy volunteers.  Top line data is currently expected in the third quarter of 2018. PL-8177, a selective melanocortin receptor 1 (MC1r) agonist peptide, is Palatin's lead clinical development candidate for ulcerative colitis and other inflammatory bowel diseases. Evolving research suggests that the MC1r system plays an important role in immunoregulation, including resolution of innate pro-inflammatory immune responses. "This is a significant milestone for Palatin (PTN), as this is our second melanocortin peptide to enter clinical development," said Stephen T. Wills, Chief Financial Officer and Chief Operating Officer of Palatin Technologies.  "Beyond bremelanotide, for which we expect to file an NDA with the FDA for female sexual dysfunction later this quarter, we continue to expand our pipeline of novel peptide therapeutics targeting the melanocortin system. We are excited about the potential of our MC1r peptides, which have the potential to treat a wide variety of inflammatory diseases.  We currently anticipate additional compounds entering clinical development later this year."

Quelle SeekingAlpha • Dosing has commenced in a Phase 1 clinical trial evaluating the safety and tolerability of Palatin Technologies' (NYSEMKT:PTN) lead candidate PL-8177 in healthy volunteers. Top-line data are expected in Q3. • PL-8177 is a selective melanocortin receptor 1 (MC1r) agonist peptide. In other words, it is a modulator of the melanocortin system which plays a key role in appetite and energy expenditure. It is being developed for the treatment of ulcerative colitis and other inflammatory bowel disorders. • Previously: Palatin to start clinical development of UC candidate PL-8177; shares up 6% premarket (Jan. 3)

Wieder dabei, starke News, aussichtsreicher Wert ✌️

Vorbörslich +4,64%

"This is a significant milestone for Palatin, as this is our second melanocortin peptide to enter clinical development," said Stephen T. Wills, Chief Financial Officer and Chief Operating Officer of Palatin Technologies. "Beyond bremelanotide, for which we expect to file an NDA with the FDA for female sexual dysfunction later this quarter, we continue to expand our pipeline of novel peptide therapeutics targeting the melanocortin system. We are excited about the potential of our MC1r peptides, which have the potential to treat a wide variety of inflammatory diseases.  We currently anticipate additional compounds entering clinical development later this year." NDA Filing dieses Quartal also nochmal bestätigt

Aber hier sind wenigstens kleine News: https://www.irdirect.net/prviewer/release/id/2926420